Reuters: Regulatory News: UPDATE 1-US FDA approves Glaxo cancer drug Votrient

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-US FDA approves Glaxo cancer drug Votrient Apr 26th 2012, 21:56 Thu Apr 26, 2012 5:56pm EDT WASHINGTON, April 26 (Reuters) - U.S. regulators gave the nod to GlaxoSmithKline Plc's Votrient for a type of sarcoma on Thursday, following a positive advisory panel vote last month. The U.S. Food and Drug Administration approved the pill for people with soft-tissue sarcoma who have already received chemotherapy. Soft-tissue sarcoma is a rare but aggressive form of cancer that afflicted about 11,000 Americans last year, 4,000 of whom died from the disease, according to the National Cancer Institute. The cancer begins in the muscles, fat or other tissues.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions